L2M-Market validation of the 3D organoid culture plates for making the human-mimicked tissue models

Currently, over 95% of new anti-cancer drugs fail during clinical trials (1). Despite significant technological advances, drug development has become slower and more expensive. The root cause is that current preclinical cancer models, such as 2D cell layers and animal models, fail to accurately recreate human biology. This makes it very difficult to predict how humans will respond to a drug before it is administered (2). Apricell is changing the way new anti-cancer drugs are developed. These drugs range from chemotherapies to newer approaches that leverage the immune system to combat cancer. Using Apricell’s proprietary 3D tissue modelling platform, researchers and drug developers can now test drugs on patient-mimicking tumor models in a way that is faster, cheaper, and more predictive than existing approaches. As the current technology serves both diagnostic and therapeutic purposes, the biggest obstacle to commercializing it is finding a target market with less regulation. Therefore, we need to conduct thorough market validation to confirm the overall feasibility of our business idea. The L2M program is an excellent opportunity to evaluate not only our product but also to gauge the market’s willingness to adopt our solution. It will also allow us to analyze our market in different customer segments and assess the broader business landscape.

Faculty Supervisor:

Mohsen Akbari

Student:

Partner:

Springboard Atlantic Inc.

Discipline:

Life Sciences

Sector:

Biotechnology; Biomanufacturing

University:

University of Victoria

Program: